Tech Company Financing Transactions
Tvardi Therapeutics Funding Round
Private investors joined a $9 million Series A funding round for Tvardi Therapeutics. This venture round closed on 9/24/2018.
Transaction Overview
Company Name
Announced On
9/24/2018
Transaction Type
Venture Equity
Amount
$9,000,000
Round
Series A
Investors
Proceeds Purpose
This financing will enable our Tvardi team to address major unmet medical needs in cancer and other diseases implicated in the STAT3 pathway.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2450 Holcombe Blvd. X
Houston, TX 77021
USA
Houston, TX 77021
USA
Phone
Website
Email Address
Not Recorded
Overview
Tvardi Therapeutics is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. Founded in 2017 and based in Houston, Texas, the company is led by experienced entrepreneurs, innovative scientists and dedicated physicians.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Imran Alibhai
Chief Scientific Officer
Jeno Gyuris
VP - Bus. Development
Sofia de Achaval
VP - R & D
Jeffrey Larson
Browse more venture capital transactions:
Prev: 9/24/2018: Auctus Biologics venture capital transaction
Next: 9/24/2018: VistaGen Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC transactions reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs